Proceedings of the 3rd International Conference on Modern Medicine and Global Health
DOI: 10.54254/2753-8818/69/2025.19712

Epigenetic Mechanisms in Neurodegenerative Diseases: Advances in Molecular Research

Wen Hai[1,a,*]

[1]*Sheffield Institute for Translational Neuroscience, University of Sheffield, The University of Sheffield, Western Bank, Sheffield, S10 2TN, UK*
a. haiwen325@gmail.com
**corresponding author*

Abstract: Recent advances in molecular biology have revolutionized our understanding of neurodegenerative disorders, revealing the intricate interplay between epigenetic mechanisms and disease progression. This review synthesizes emerging evidence on how epigenetic modifications, including DNA methylation patterns, histone alterations, and non-coding RNA (ncRNA) dynamics, orchestrate neural degeneration and potential therapeutic interventions. We critically examine how aberrant epigenetic signatures in genes such as APP and SNCA drive pathological cascades in conditions like Alzheimer's disease (AD) and Parkinson's disease (PD). Through systematic analysis of recent literature, we evaluate the diagnostic potential of epigenetic biomarkers and explore promising therapeutic strategies targeting these modifications. This comprehensive review provides a framework for understanding epigenetic mechanisms in neurodegeneration while highlighting innovative approaches for clinical intervention.

Keywords: Neurodegenerative diseases, Epigenetic modifications, DNA methylation, Histone modifications, Epigenetic biomarkers

1. Introduction

The human nervous system faces an array of progressive disorders known as neurodegenerative diseases, which manifest through selective neuronal deterioration in specific brain regions. These conditions present complex pathological signatures, encompassing neuronal dysfunction, inflammatory responses, protein aggregation abnormalities, and destabilization of cellular homeostatic mechanisms. Two prominent examples illustrate the distinct pathological features: AD exhibits characteristic amyloid plaque deposits and neurofibrillary tangles, while PD manifests through the distinctive presence of Lewy body inclusions [1].

The field of epigenetics has emerged as a crucial framework for understanding gene regulation beyond traditional DNA sequence analysis. Within neural tissues, epigenetic control operates through an intricate interplay of mechanisms, primarily consisting of DNA methylation patterns, modifications to histone proteins, and the action of long non-coding RNAs (lncRNAs). These regulatory systems collectively orchestrate a wide spectrum of cellular processes and organismal functions [2].

Contemporary research has revealed the profound impact of epigenetic regulation in neurodegenerative pathologies. The expanding body of evidence demonstrates that epigenetic

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/69/2025.19712

mechanisms serve not only as key contributors to disease development but also as potential windows into novel diagnostic and therapeutic approaches. This intersection of epigenetics and neurodegeneration opens promising avenues for advancing personalized medicine strategies [3].

By investigating the molecular landscape through an epigenetic lens, researchers have gained unprecedented insights into neurodegenerative disease mechanisms. The study of DNA methylation patterns, histone modifications, and long non-coding RNA functions presents unique opportunities for identifying early diagnostic biomarkers. Furthermore, these epigenetic elements may serve as valuable targets for innovative therapeutic interventions, potentially leading to more effective treatment strategies for neurodegenerative conditions [4].

2. Theoretical Research

2.1. The Role of DNA Methylation in Neurodegenerative Diseases

The epigenetic landscape of neurodegenerative disorders is prominently shaped by DNA methylation, a fundamental regulatory mechanism that predominantly targets CpG island regions. This process involves DNA methyltransferases catalyzing the addition of methyl groups to cytosine residues within CpG dinucleotides, generating 5-methylcytosine (5mC) [5]. The dynamic and reversible nature of this modification allows precise control over DNA accessibility and stability, thereby orchestrating gene expression patterns crucial for neuronal survival, differentiation, and tissue-specific functions. Mounting evidence suggests that dysregulation of methylation patterns can compromise neuronal viability and function, potentially initiating or accelerating neurodegenerative processes [4].

In the context of AD and PD, distinctive methylation signatures have emerged. Notable alterations in AD include hypomethylation of critical genes such as APP, PSEN1, and SERT1, observed consistently across both neural and peripheral tissues. Conversely, specific genes including TREM2 and ANK1 exhibit increased methylation levels [6]. In PD, the epigenetic regulation of the SNCA gene, encoding alpha-synuclein, is of particular significance. PD patients exhibit marked hypomethylation of the SNCA promoter region, potentially driving aberrant gene expression and subsequent protein aggregation. This process is further influenced by demethylation events within SNCA's first intronic region, creating a cascade that may accelerate the formation of characteristic Lewy body inclusions [7].

The advancing field of epigenetic research has illuminated DNA methylation's potential as a diagnostic tool for neurodegenerative conditions. Distinct methylation patterns in disease-associated genes offer promising biomarker candidates. For instance, AD's methylation profile includes reduced methylation of APP and PSEN1 coupled with BDNF hypermethylation, while PD demonstrates characteristic hypomethylation of SNCA and LRRK2 [6,8]. Notably, these epigenetic modifications are detectable in peripheral blood, suggesting possibilities for developing non-invasive diagnostic approaches. Furthermore, temporal analysis of methylation patterns may provide insights into disease progression stages, enabling timely therapeutic interventions. These dynamic epigenetic signatures not only enhance our understanding of disease mechanisms but also present opportunities for developing stage-specific treatment strategies [9].

2.2. The Role of Histone Modifications

The intricate regulation of gene expression in neurodegenerative conditions is significantly influenced by post-translational modifications (PTMs) of histone proteins. PTMs involve chemical alterations to histone tail domains and globular cores, including acetylation, methylation, phosphorylation, ubiquitination, and ADP-ribosylation [2]. Within neural tissues, this sophisticated epigenetic machinery governs neuron-specific gene expression patterns, modulating crucial processes such as neural development, synaptic plasticity, and neuroprotective mechanisms. The precise maintenance

DOI: 10.54254/2753-8818/69/2025.19712

of these histone-mediated regulatory networks is fundamental for preserving neuronal functionality and adaptability, with disruptions potentially triggering or exacerbating neurodegenerative pathologies [4].

In AD, a notable reduction in histone H3 and H4 acetylation levels has been observed, potentially compromising the expression of genes critical for cognitive function and synaptic maintenance. Of particular significance is the elevation of H3K27me3 (trimethylation at lysine 27 of histone H3) in AD-affected neural tissues [7]. This repressive epigenetic mark may silence essential genes involved in neuronal survival and metabolic homeostasis, potentially accelerating neurodegeneration. The epigenetic landscape in PD also presents unique alterations, particularly in the context of SNCA gene regulation. Specific patterns of histone methylation and acetylation modifications influence alpha-synuclein aggregation dynamics. Furthermore, abnormal deacetylation patterns have been observed in the LRRK2 gene promoter region, potentially contributing to dysregulated gene expression and accelerating the selective degeneration of dopaminergic neurons within the substantia nigra [8].

2.3. The Therapeutic Potential of Epigenetic Modifications

The potential for leveraging epigenetic modifications as a therapeutic approach for neurodegenerative diseases is gaining increased recognition. Histone deacetylase (HDAC) inhibitors have shown promise by preventing the removal of acetyl groups from histones, ensuring that genes remain in an active state and promoting the survival and plasticity of neurons. Several HDAC inhibitors have demonstrated improvements in cognitive and motor functions when tested in models of neurodegenerative diseases [10]. These results suggest that by restoring histone acetylation levels and maintaining the expression of neuroprotective genes, HDAC inhibitors may slow the progression of neurodegeneration. Regulating epigenetic modifications with the goal of restoring the expression of genes that protect neurons represents a promising strategy for treating neurodegenerative disorders. Progress in this area could lay the groundwork and provide clinical tools for early interventions and personalized therapies for diseases such as AD, PD, and others [11].

3. Challenges in Neurodegenerative Diseases: Oxidative Stress, Non-Coding RNAs, and Neuroinflammation

Oxidative stress (OS) is a common feature of neurodegenerative disorders, defined as a pathological state in which the accumulation of reactive oxygen species (ROS) in cells exceeds the capacity of antioxidant defenses, resulting in cellular damage. In neurodegenerative diseases, OS is considered a critical driver of disease progression. The gradual buildup of specific ROS can lead to mitochondrial dysfunction, protein aggregation, and inflammatory responses. Furthermore, OS exacerbates neuronal death by activating various cellular signaling pathways, such as the NF-κB and MAPK pathways, which regulate apoptosis, inflammatory responses, and cell cycle abnormalities [12].

Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), play crucial roles in regulating gene expression and modulating oxidative stress responses. miRNAs, a class of small RNAs predominantly localized in the cytoplasm, are particularly implicated in oxidative stress. Various miRNAs, such as miR-200c, miR-141, miR-21, and miR-145, have been identified as key players in the oxidative stress response [13].

Neuroinflammation, which refers to an inflammatory response initiated by the activation of immune cells within the central nervous system (CNS), is another hallmark of neurodegenerative diseases. While low-level neuroinflammation is a protective physiological response that safeguards the brain against internal and external harmful factors, its chronic and prolonged presence can adversely affect the CNS and contribute to neurodegenerative processes [2]. This response involves various cell types within the CNS, including astrocytes and microglia. Microglia, as the principal

DOI: 10.54254/2753-8818/69/2025.19712

immune cells of the CNS, play a central role in neuroinflammation. Their activation leads to the release of various inflammatory and cytotoxic factors, resulting in neuroinflammation and neurodegenerative damage. For example, in AD, microglia can be activated by amyloid-beta (Aβ), leading to the release of pro-inflammatory cytokines such as IL-1β and TNF-α, which further exacerbate neuronal damage [14].

4. Therapeutic Innovations and Future Directions

Recent developments in epigenetic therapeutics have yielded promising approaches for targeting aberrant DNA methylation in neurodegenerative conditions. Novel methylation inhibitors demonstrate enhanced specificity and reduced off-target effects compared to traditional agents. Clinical investigations of these compounds reveal their potential to normalize expression of key genes including APP, MAPT, and SNCA, offering new therapeutic possibilities [11]. Emerging evidence supports the development of personalized therapeutic strategies based on individual epigenetic profiles. Advanced computational methods enable prediction of treatment responses based on patient-specific epigenetic signatures, moving toward truly personalized intervention strategies [3].

Contemporary research reveals distinct epigenetic signatures associated with different stages of neurodegeneration. Integration of multiple epigenetic markers, including DNA methylation patterns, histone modifications, and ncRNA profiles, provides enhanced diagnostic accuracy compared to traditional single-marker approaches [9]. Next-generation research strategies increasingly emphasize comprehensive multi-omics analysis, integrating epigenetic data with other molecular profiles. This holistic approach provides deeper insights into disease mechanisms and potential therapeutic targets [1].

5. Summary and Future Perspectives

This review synthesizes current understanding of epigenetic mechanisms in neurodegeneration while highlighting emerging therapeutic strategies. The complex interplay between different epigenetic modifications in disease progression suggests the need for integrated therapeutic approaches. Future developments in this field will likely focus on personalized intervention strategies based on individual epigenetic profiles, supported by advanced technological platforms and comprehensive multi-omics analysis. This evolution in understanding and treatment approaches offers new hope for more effective management of neurodegenerative conditions.

References

[1] *Qazi TJ, Quan Z, Mir A, Qing H. Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation. Mol Neurobiol. 2018;55(2):1026-1044. doi:10.1007/s12035-016-0357-6*

[2] *Hwang JY, Aromolaran KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci. 2017;18(6):347-361. doi:10.1038/nrn.2017.46*

[3] *Wen KX, Milic J, El-Khodor B, et al. The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS One. 2016;11(12):e0167201. doi:10.1371/journal.pone.0167201*

[4] *Lardenoije R, Iatrou A, Kenis G, et al. The epigenetics of aging and neurodegeneration. Prog Neurobiol. 2015;131:21-64. doi:10.1016/j.pneurobio.2015.05.002*

[5] *Berson A, Nativio R, Berger SL, Bonini NM. Epigenetic Regulation in Neurodegenerative Diseases. Trends Neurosci. 2018;41(9):587-598. doi:10.1016/j.tins.2018.05.005*

[6] *Stoccoro A, Coppedè F. Role of epigenetics in Alzheimer's disease pathogenesis. Neurodegener Dis Manag. 2018;8(3):181-193. doi:10.2217/nmt-2018-0004*

[7] *Klein HU, McCabe C, Gjoneska E, et al. Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer's human brains. Nat Neurosci. 2019;22(1):37-46. doi:10.1038/s41593-018-0291-1*

[8] *Zamudio-Ochoa A, Camacho-Arroyo I. Epigenetic Modifications in the Brain of Patients with Parkinson's Disease. J Mol Neurosci. 2021;71(3):603-613. doi:10.1007/s12031-020-01692-8*

[9] *Mendes FCG, Gomes KC, Ribeiro MF, et al. Epigenetic Biomarkers for Early Detection of Alzheimer's Disease: A Systematic Review. Curr Alzheimer Res. 2021;18(5):424-446. doi:10.2174/1567205018666210510133353*

[10] *Yang SS, Zhang R, Wang G, Zhang YF. The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease. Transl Neurodegener. 2017;6:19. doi:10.1186/s40035-017-0089-1*

[11] *Mitra S, Behbahani H, Eriksdotter M. Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF. Front Neurosci. 2019;13:38. doi:10.3389/fnins.2019.00038*

[12] *Butterfield DA. The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med. 2014;74:157-174. doi:10.1016/j.freeradbiomed.2014.06.006*

[13] *Konovalova J, Gerasymchuk D, Parkkinen I, Chmielarz P, Domanskyi A. Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases. Int J Mol Sci. 2019;20(23):6055. doi:10.3390/ijms20236055*

[14] *Yang Q, Wang Y, Jia C, et al. The Crosstalk Between Microglia and Neurons in Neuroinflammation Induced by α-Synuclein in Parkinson's Disease. Front Immunol. 2021;12:656455. doi:10.3389/fimmu.2021.656455*